<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02981199</url>
  </required_header>
  <id_info>
    <org_study_id>MM-MSCT-001</org_study_id>
    <nct_id>NCT02981199</nct_id>
  </id_info>
  <brief_title>Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients</brief_title>
  <official_title>A Prospective, Multi-center, Randomized Controlled Trial of Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chen Wenming</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>307 Hospital of PLA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <brief_summary>
    <textblock>
      Comparison of the efficacy and safety of microtransplantation and autologous transplantation
      in the treatment of ≥PR multiple myeloma patients, 2-year PFS and OS were also been observed.
      To identify the role of microtransplantation in the treatment of multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NDMM patients induction therapy with 4 cycles PCD/PAD regimen, achieve ≥PR, eligible for SCT,
      were randomly divided into two arms. One arm receive microtransplantation, and the other
      accept auto-SCT. Comparison of the efficacy and safety of two arms, 2-year PFS and OS were
      also been observed. Clear the above program related hematopoietic recovery, remission rate,
      infection and recurrence rate, survival rate and the formation of micro inlay, minimal
      residual disease and GVHD, etc. To identify the role of microtransplantation in the treatment
      of multiple myeloma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of complete remission</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>minimal residual disease</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hematopoietic recovery</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infection</measure>
    <time_frame>3 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GVHD</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Microtransplantation</condition>
  <condition>Autologous Stem Cell Transplantation</condition>
  <condition>Multiple Myeloma in Relapse</condition>
  <arm_group>
    <arm_group_label>Micro-SCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients treated with microtransplantation. [VMD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; melphalan 60mg/m2 d1; dexamethasone 20mg d1,2,4,5,8,9,11,12) + low dose allogeneic stem cell transplantation]×4cycles; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×1cycle; then maintenance therapy with thalidomide 100mg/d.
microtransplantation = [VMD regimen chemotherapy+ low dose allogeneic stem cell transplantation]×4cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Auto-SCT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients treated with Auto-SCT. conditioning with Mel+Vel regimen (melphalan 200mg/m2 d-2, bortezomib 1.3mg/m2 d-6,-3,+1,+4) + autogeneic stem cell transplantation; [PTD chemotherapy(bortezomib 1.3mg/m2 d1,4,8,11; thalidomide 100mg/d, dexamethasone 20mg d1,2,4,5,8,9,11,12)]×4cycle; then maintenance therapy with thalidomide 100mg/d.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>stem cell transplantation</intervention_name>
    <description>conditioning with chemotherapy [VMD regimen(bortezomib, melphalan, dexamethasone) or Mel+Vel regimen(melphalan, bortezomib)], then stem cell transfusion</description>
    <arm_group_label>Micro-SCT</arm_group_label>
    <arm_group_label>Auto-SCT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis MM compliance with IMWG diagnostic criteria(2014)

          2. induction therapy with 4 cycles PCD/PAD regimen, achieve ≥PR

          3. KPS ≥60，ECOG≤2 4）Age 18-65，eligible for SCT 5）Heart function &lt; II level (NYHA
             standard) and ejection fraction &gt; 50% -

        Exclusion Criteria:

          1. KPS＜60

          2. Allergy to bortezomib,epirubicin, or drug ingredients

          3. Severe hepatitis and organ dysfunction: a serious infection has not been controlled;
             cardiac ejection fraction &lt;50%, serum bilirubin &gt;3mg/dl, severe abnormal results of
             liver function test (AST is greater than 3 times the upper limit), severe renal
             injury; central nervous system disorders, uncontrolled mental illness

          4. With more than 2 bortezomib associated with peripheral neuropathy or neuralgia
             patients

          5. Patients with active stage of the herpes zoster

          6. Women in pregnancy or lactation

          7. MM with AL or EM plasma cell tumor

          8. The patient refused to accept the above treatment and signature

          9. Donor does not meet the requirements: including HIV positive, active hepatitis B, bone
             marrow disease, donor refused to provide hematopoietic stem cells and do not agree to
             sign.

         10. Epirubicin / other anthracyclines previously accumulated more than 240mg/m2 -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenming Chen, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guorong Wang, doctor</last_name>
    <phone>+861085231572</phone>
    <email>blunlake@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wenming Chen, doctor</last_name>
    <phone>+8685231581</phone>
    <email>wenming_chen@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guorong Wang, doctor</last_name>
      <phone>+861085231572</phone>
      <email>blunlake@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wenming Chen, doctor</last_name>
      <phone>+861085231581</phone>
      <email>wenming_chen@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2016</study_first_submitted>
  <study_first_submitted_qc>November 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2016</study_first_posted>
  <last_update_submitted>December 15, 2016</last_update_submitted>
  <last_update_submitted_qc>December 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Chen Wenming</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>microtransplantation</keyword>
  <keyword>multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Melphalan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

